Business Wire

OR-GUROBI-OPTIMIZATION

10.4.2024 20:33:26 CEST | Business Wire | Press release

Share
Gurobi to Launch Free Massive Open Online Course (MOOC) on Optimization for Data Scientists

Gurobi Optimization, LLC, the leader in decision intelligence technology, in collaboration with Dr. Joel Sokol, Harold E. Smalley Professor in Georgia Tech’s H. Milton Stewart School of Industrial and Systems Engineering, and founding Director of Georgia Tech’s Master of Science in Analytics degree, today announced the launch of a new free online course: "Introduction to Optimization Through the Lens of Data Science." The course, which aims to introduce optimization to data science learners, is now available online on Udemy.

In today’s data-driven world, the ability to make informed, optimal decisions is more crucial than ever. Data scientists are adept at extracting insights from data, but leveraging those insights to make the best possible decisions requires a deep understanding of optimization. This course fills a critical gap in the current educational landscape, offering a comprehensive introduction to optimization tailored for data science professionals.

Course Features:

  • Expert Instruction: Led by Dr. Joel Sokol, this course draws on his extensive experience in optimization and analytics to provide learners with both theoretical knowledge and practical skills.
  • Tailored for Data Scientists: The curriculum is designed with data scientists in mind, focusing on practical applications of optimization in data science rather than deep theoretical concepts.
  • Comprehensive Curriculum: The course covers motivation, modeling, and real-world cases, ensuring learners understand not only how to use optimization, but also why it’s important.
  • Hands-On Learning: Through interactive examples, case studies, and the use of the Gurobi Optimizer and Python’s gurobipy library, students will gain hands-on experience in solving optimization problems.
  • Code-Focused Examples: The course is designed to meet data scientists where they are in their problem-solving journey, presenting the Python code right alongside the mathematical and English language versions of each problem.

Students can enroll for free on Udemy and work through the course and 130+ examples at their own pace. Educators are also encouraged to integrate this course material into their curriculum to provide students with a cutting-edge blend of data science and optimization skills. The course is designed to prepare students for the challenges of the modern world, equipping them with highly sought-after skills in the industry.

“We’re excited to partner with Dr. Joel Sokol to launch this much-needed online course,” explained Gurobi CEO, Duke Perrucci. “By making this learning accessible to data scientists around the world, we are not just educating the next generation of decision-makers—we’re empowering them to solve some of the world's most challenging problems.”

"Introduction to Optimization Through the Lens of Data Science, Parts 1 - 4" is now open for enrollment on Udemy. Data scientists, educators, and students interested in expanding their skill set and understanding of optimization are invited to register for this innovative, free course.

For more information and to enroll, please visit the Gurobi website.

About Gurobi Optimization

With Gurobi’s decision intelligence technology, customers can make optimal business decisions in seconds. From workforce scheduling and portfolio optimization to supply chain design and everything in between, Gurobi identifies the optimal solution, out of trillions of possibilities.

As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98% customer satisfaction rating.

Founded in 2008, Gurobi has operations in the Americas, Europe, and Asia. It serves customers in nearly all industries, including organizations like SAP, Air France, and the National Football League. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410048978/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 13:40:00 CET | Press release

One provider for identity, compliance and fraud prevention across 50+ countries, with a single integrated platform. Fourthline and Veridas combined will create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US; on track for 200 million verifications in 2026. With a projected combined revenue of more than €50m in 2026 and both businesses EBITDA-positive at closing, the company expects to reach €85m annual recurring revenue in 2029. Financials: The transaction includes funding of up to €65m provided by existing shareholder Finch Capital, new equity investment from Seaya Andromeda and debt financing from Ashgrove Capital. Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full rele

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release

Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment

Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 12:26:00 CET | Press release

Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh

BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 12:01:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b

Dubai Culture Unveils ISEA2026 Online Academic Programme3.11.2026 11:58:00 CET | Press release

Dubai Culture and Arts Authority has unveiled the academic programme for the 31st International Symposium on Electronic/Emerging Art (ISEA2026), taking place in Dubai from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data, and Identity’. The symposium will explore the intersections of art, science and technology and examine the future of electronic arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103057351/en/ Dubai Culture unveils ISEA2026 Online Academic Programme (Photo: AETOSWire) The symposium, organised by Dubai Culture in partnership with Zayed University, is set to be the largest edition in its history. It will feature opening remarks by Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture, and Her Excellency Hala Badri, Director General of Dubai Culture, alongside keynote presentations by Katherine Hayles, Distinguished Research Professor at the U

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye